Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib, Venetoclax, and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
NCT06454409Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Apr 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regorafenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoints: Dose-limiting toxicity at 28 days and Incidence of adverse events. Started Apr 2025; status: suspended.
02
Drugs
regorafenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06454409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454409.